These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 21198277

  • 1. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence.
    Kundal VK, Pandith AA, Hamid A, Shah A, Kundal R, Wani SM.
    Asian Pac J Cancer Prev; 2010; 11(5):1279-82. PubMed ID: 21198277
    [Abstract] [Full Text] [Related]

  • 2. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A, Kumar R, Gupta NP.
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
    Lee KH.
    Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
    [Abstract] [Full Text] [Related]

  • 4. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A.
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.
    Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, Fritsche HA, McDougal WS.
    J Urol; 1998 Feb; 159(2):394-8. PubMed ID: 9649246
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S, Biri H, Sinik Z, Küpeli B, Alkibay T, Bozkirli I.
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [Abstract] [Full Text] [Related]

  • 7. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
    Smrkolj T, Mihelič M, Sedlar A, Sterle I, Osredkar J, Sedmak B.
    Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
    [Abstract] [Full Text] [Related]

  • 8. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
    Moonen PM, Kiemeney LA, Witjes JA.
    Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
    [Abstract] [Full Text] [Related]

  • 9. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
    Kapila K, Kehinde EO, Anim JT, Mojiminiyi OA, Vinsu A, George SS, Al-Maghrebi M, Al-Mulla F.
    Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356
    [Abstract] [Full Text] [Related]

  • 10. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF, Casella R, Wians FH, Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI.
    Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [Abstract] [Full Text] [Related]

  • 11. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
    Poulakis V, Witzsch U, De Vries R, Altmannsberger HM, Manyak MJ, Becht E.
    BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
    [Abstract] [Full Text] [Related]

  • 12. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.
    Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y.
    JAMA; 2006 Jan 18; 295(3):299-305. PubMed ID: 16418465
    [Abstract] [Full Text] [Related]

  • 13. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
    Önal B, Han Ü, Yilmaz S, Köybasioglu F, Altuğ U.
    Diagn Cytopathol; 2015 Apr 18; 43(4):307-14. PubMed ID: 25488052
    [Abstract] [Full Text] [Related]

  • 14. NMP22 in transitional cell carcinoma of the urinary bladder.
    Su CK, Yang CR, Horng YY, Kao YL, Ho HC, Ou YC, Cheng CL.
    J Chin Med Assoc; 2003 May 18; 66(5):294-8. PubMed ID: 12908572
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y, Goktas S, Kilic S, Yaman H, Onguru O, Peker AF.
    Ann Clin Lab Sci; 2006 May 18; 36(1):31-8. PubMed ID: 16501234
    [Abstract] [Full Text] [Related]

  • 16. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.
    Shariat SF, Casella R, Monoski MA, Sulser T, Gasser TC, Lerner SP.
    J Urol; 2003 Dec 18; 170(6 Pt 1):2244-7. PubMed ID: 14634389
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS, Bagiella E, Sawczuk AT, Yun EJ.
    Cancer Detect Prev; 2000 Dec 18; 24(4):364-8. PubMed ID: 11059567
    [Abstract] [Full Text] [Related]

  • 19. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
    Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G, Marberger M.
    J Urol; 1998 Jun 18; 159(6):1876-80. PubMed ID: 9598479
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.